By Prof. Dr Lieven Annemans, expert trainer of the courses Health Economics for Non-Health-Economists, Basics of Health Economics, and Critical New HTA Developments in Europe: Challenges & Solutions
For many non-health-economists, understanding what makes a health economic evaluation robust and decision-relevant isn't always straightforward.
Whether an evaluation withstands scrutiny usually comes down to a handful of choices:
To support pharma professionals who work with health economic data, whether in Medical Affairs, Market Access or Marketing, Prof. Dr Lieven Annemans has listed 10 guidelines that reflect international best practice.
Want to take these tips with you?
Download the Health Economic Evaluation Review Tool below 👇
Economic models must start with a well-defined patient population. Vague definitions like “patients at risk of stroke” don’t provide enough context for meaningful conclusions. A good example: “Spinal cord stimulation in patients with failed back surgery, average age 52, with predominantly back pain and an average pain duration of 4 years.”
Cost-effectiveness is always relative. The new treatment should be compared to the most likely alternative in clinical practice, not a placebo or outdated option. A thorough description of both treatment strategies is important, including known side effects and usage patterns.
Is the analysis conducted from a payer, healthcare system, or societal perspective? This matters. For instance, the societal perspective might include productivity losses, especially relevant in diseases like depression, while payer perspectives often do not.
The assumptions behind the model should be clearly explained. Where possible, model outputs should be validated against real-world data. For example: comparing predicted stroke rates under current care with those observed in practice.
Costs should be broken down into all relevant components (e.g. acute care, follow-up, re-admissions) and linked to the defined patient population. All sources must be disclosed. Over-simplified assumptions can lead to misleading results.
Data inputs should come from high-quality sources and reflect the population being studied. When it comes to outcomes, the QALY remains the standard across many countries. Using the most relevant data for the base case is key.
The time horizon should be long enough to capture all significant costs and effects. Results should be tested for different horizons to show how conclusions might change over time.
Every model involves uncertainty. High-quality evaluations include sensitivity analyses, both one-way (e.g. Tornado diagrams) and probabilistic (PSA), to show how results vary with changes in key inputs and assumptions.
If the time horizon extends beyond one year, future costs and benefits should be discounted. Including alternative discount rates in sensitivity analysis is good practice.
A strong conclusion is based on the PICOS framework: Patient, Intervention, Comparator, Outcome, and Study Design. Rather than saying “the treatment is cost-effective,” clarify for whom, compared to what, and over what time frame.
These 10 guidelines are increasingly important as health economic evaluations influence funding, pricing, and access decisions in a growing number of countries. By applying or recognising these principles, you can better evaluate evidence and contribute to stronger, more credible value communications.

Continue your learning from Lieven
If you’d like to learn more from Lieven, CELforPharma also offers a 2-day, hands-on course where you'll learn how to:
Don’t miss the latest insights from our expert faculty
Subscribe to our newsletter to: